Merck KGaA in Darmstadt, Germany, recently welcomed Hamilton Thorne and ZEISS as the two most recent members of the company’s Global Fertility Alliance, which already includes Illumina, Genea and Merck KGaA.
The goal of the alliance is to promote the standardization of processes that are used for assisted reproductive treatments (ARTs) developed in laboratories. To do this, the alliance maintains a partnership that furthers the excellence in processes and technologies for fertility and ARTs.
“Through our work with the fertility community, we know that ART outcomes strongly depend on routines and technologies applied in laboratories,” Rehan Verjee, chief marketing and strategy officer at Merck KGaA, said. “As such, we are committed to overcoming current variation in ART practices and techniques. We are working in the alliance to support the development of global standards in ART laboratories. We understand this as a critical factor for ensuring a consistently high level of performance across centers and countries, ultimately supporting the goal of women and couples of having a baby.”
The experience of each company will be used to the greatest advantage of the overall partnership.
“ZEISS has a strong heritage in the development of specialized microscopes, and we are committed to using our expertise in this field to drive the standardization of ART processes and techniques further,” Peter Kraemer, director of market segment education and routine at ZEISS Microscopy Business Group, said. “We are impressed by the alliance’s progress so far and look forward to contributing to improvements in ART practices through technology innovation.”
